24 & 25 of October 2019Xi'an, CHINA

Xi'an 2019

IBBS is pleased to introduce the first Convention on Cancer and Biomarkers at Xi’an, China
Co-Organized by International Bio-Business Services, Sino-French school of Oncology, Xidian University (China), University of Evry (France), University of Paris-Saclay and the French Embassy in China
View details

2019 XI'AN Convention on Cancer and Biomarkers



Aim event

Biomarkers are now strongly associated with the treatments of cancer patients. They are involved in all many aspects including at least the new anticancer drug discovery, the molecular target engagement, the new anticancer drug developments, the tumor subtype selection and the clinical management of patients.

Participants from academic and medical institutions as well as industrial players will present and discuss their knowledge and views on the current and the future biomarkers in cancer patients. Lectures and round table sessions will structure the meeting agenda.

This Convention is co-organized by International Bio-Business Services, Sino-French school of Oncology, Xidian University (China), University of Evry (France), University of Paris-Saclay and the French Embassy in China. Such convention will strengthen international cooperation and facilitate the establishment of new interactive programs.

The event will take place within the Xidian University, Xi’an, (China) the 24 & 25 of October 2019. Registration and sponsoring are already open.

This Convention is financially supported by the co-organizers and other Institutions and private companies.

Each of you is welcome to participate to this Convention, please contact IBBS at contact@ibbs-services.com

Dr Grégoire PREVOST CEO of IBBS & Professor Bo Hu Xidian University

0

speakers

0

days

workshops

0

business convention

Co-Organizers



IBBS

IBBS

International Bio-Business Services

IBBS can put a team of recognized experts at your disposal to advance your projects IBBS is a partner of LS LEAD in France and the USA that comprises more than 80 experts in Life Sciences

See more

Institut Curie

IBBS can put a team of recognized experts at your disposal to advance your projects IBBS is a partner of LS LEAD in France and the USA that comprises more than 80 experts in Life Sciences

French comprehensive cancer center

Xidian University (China)

Xidian University

Xidian University (XDU) dedicates primarily to the electronics and information research and education, with an integration of a wide range of academic subjects covering engineering, science, humanities and social sciences.


Huazhong University of Science & Technology

University of Paris-Saclay

University of Paris-Saclay

The Université Paris-Saclay enjoys exceptional scientific potential, bringing together founding members of varied but complementary natures.

See more

University of Paris-Saclay

The Université Paris-Saclay enjoys exceptional scientific potential, bringing together founding members of varied but complementary natures.

Sino French Bio Center

Sino French School of Oncology

Co-founded by Prof Jianfeng Liu (HUST) and Dr Grégoire Prevost (CIPREVO) in 2012

Supported by the Ambassade de France en Chine
Background: Cancer is a major health problem in the world, however, education efforts against cancer is still not uniform worldwide. It has been recognized that a complete and proper teaching portfolio should include learning on cancer control (epidemiology, prevention and screening)...

See more

Sino French School of Oncology

Supported by the Ambassade de France en Chine
Background: Cancer is a major health problem in the world, however, education efforts against cancer is still not uniform worldwide. It has been recognized that a complete and proper teaching portfolio should include learning on cancer control (epidemiology, prevention and screening), clinical skills, patients communications skills and palliative care.
Mission: Increase the connections between France and China to strength the progress against Cancer – Particularly in the Hubei province.
Our approach: Introduction to young professionals all the major aspects of oncology to progress against cancer. The course integrates the complexity from the basic principles of oncogenesis to diagnosis and therapeutic management of the most aggressive tumors.

Sino French Bio Center

PopsiCube

Connecting Clinical Research

Our expertise stems from many years of experience spent inside the largest CRO or pharmaceutical companies. We always considered IT as a valuable tool and as a way to improve and industrialize processes. It is our in-depth knowledge of pharmaceutical R&D which allows us to transform these tools to support a real advance in your clinical projects...

See more

PopsiCube

Our expertise stems from many years of experience spent inside the largest CRO or pharmaceutical companies. We always considered IT as a valuable tool and as a way to improve and industrialize processes. It is our in-depth knowledge of pharmaceutical R&D which allows us to transform these tools to support a real advance in your clinical projects.
The origin of Popsi Cube is a convergence between a solid clinical process and effective IT tools.
A CRO with integrated tools to address the entire clinical research functional scope.
A successful project management requires top quality human resources but also a set of tools supporting a simple, pertinent and effective decision process. Popsi Cube did not find any off-the-shelf system that would meet these objectives. We therefore have developed a set of tools specifically adapted to our services.

Sino French Bio Center

MyPharmaCompany

Is the first European crowdfunding company solely dedicated to healthcare

My Pharma Company intends to fulfill a significant unmet need by financing “proof of concept”, early stage clinical studies or market access studies. These are often difficult to fund with traditional financing options (business angels, venture capital) yet they are critical to establish the safety and/or efficacy of new medicines or in securing regulatory approval...

See more

MyPharmaCompany

My Pharma Company intends to fulfill a significant unmet need by financing “proof of concept”, early stage clinical studies or market access studies. These are often difficult to fund with traditional financing options (business angels, venture capital) yet they are critical to establish the safety and/or efficacy of new medicines or in securing regulatory approval for medical devices or diagnostic tests.

Sino French Bio Center

Université d'Evry

Multidisciplinary university, associated to the Université Paris-Saclay

The Université d’Evry-Val-d’Essonne is located 30 km south of Paris. It is a multidisciplinary university, associated to the Université Paris-Saclay, with whom it shares Research Masters and PhD schools. The UEVE offers to its 10 000 students 160 diplomas distributed over 5 research...

See more

Université d'Evry

The Université d’Evry-Val-d’Essonne is located 30 km south of Paris. It is a multidisciplinary university, associated to the Université Paris-Saclay, with whom it shares Research Masters and PhD schools. The UEVE offers to its 10 000 students 160 diplomas distributed over 5 research and formation poles. The UEVE includes a School of Engineering (ENSIIE) and a Vocational training center. UEVE is strongly linked to the Evry Genopole Biocluster. UEVE and Genopole have in common 18 Research Laboratories.

LSLEAD

Life Sciences Leadership School

Acquire solid experience-based skills

Based in Paris, LS LEAD purpose is to achieve knowledge transfer to talented professionals without disrupting their professional lives: Achieve the transfer of solid experience-based skills by recognized expert professionals in innovative Life Sciences Businesses To talented professionals who intend to become leaders ready to successfully create and manage innovative health care companies in a competitive international environment.

See more

Life Sciences Leadership School

Based in Paris, LS LEAD purpose is to achieve knowledge transfer to talented professionals without disrupting their professional lives: Achieve the transfer of solid experience-based skills by recognized expert professionals in innovative Life Sciences Businesses To talented professionals who intend to become leaders ready to successfully create and manage innovative health care companies in a competitive international environment.

Confirmed Speakers

Meet the professionals



Dr GREGOIRE PREVOST

Dr GREGOIRE PREVOST

Founder, Owner and CEO of CIPREVO

Grégoire is now CEO of CIPREVO based in France which is a unique expertise provider supporting research and development projects in Oncology. Grégoire brings 29 years of experience in Oncology research and development. He obtained his PhD in Molecular and Cellular Biology in 1989 at the Institut Pasteur of Paris/ University of Tours (France)

See more


Dr GREGOIRE PREVOST

Grégoire is now CEO of CIPREVO based in France which is a unique expertise provider supporting research and development projects in Oncology. Grégoire brings 29 years of experience in Oncology research and development. He obtained his PhD in Molecular and Cellular Biology in 1989 at the Institut Pasteur of Paris/ University of Tours (France), and continued his scientific career as a post-doctorate at IOCMH (Bobigny, France) and BIOMEASURE (Milford, MA, USA). In 1995, he was appointed as Oncology research leader at Beaufour-IPSEN (Les Ulis, France) and held progressive positions at IPSEN, among which Oncology Translational Research Director, Oncology Scientific Affairs Director and member of the Oncology Portfolio Management Team. In March 2011, Grégoire joined InteRNA Technologies (Utrecht, The Netherlands) as Chief Development Officer and in 2013 created his own company CIPREVO to support R&D Oncology projects. He has participated to the transfer of 3 drug candidates to the clinic and has been a significant contributor to Oncology field with more than 100 scientific publications and patent families. In addition in 2012, he co-founded the Sino-french School of Oncology in Wuhan with Professor Jianfeng Liu from HUST, Wuhan.

Bo Hu

School of Life Science and Technology， Xidian University

Bo Hu got his PhD in Inorganic Chemistry in 2008 at the University of Science and Technology of China (China), and continued his scientific career as a post-doctorate at the University of Science and Technology of China (Hefei, China),

See more

Bo Hu

Bo Hu got his PhD in Inorganic Chemistry in 2008 at the University of Science and Technology of China (China), and continued his scientific career as a post-doctorate at the University of Science and Technology of China (Hefei, China), Northwestern University (Evanston, IL, USA), University of Cincinnati (Cincinnati, OH, USA), and Washington University in St. Louis (St. Louis, MO, USA). In 2015, he joined School of Life Science and Technology in the Xidian University. He has authored and co-authored more than 30 refereed journal publications published in Adv. Mater., Adv. Funct. Mater., ACS Nano etc. (citations 2292, H index= 18), 2 invited book chapters, and 6 patents. His research interests are focused on the molecular imaging and sensing, which has the characterization of multidisciplinary cross connection. Based on the clinic problems, he uses multi-technology, including nanotechnology, 3D printing, microfluidics, molecular biology, artificial intelligence and electronic engineering for the development of diagnosis system of diseases.

Willy Mathot

Willy Mathot

Attorney

Willy is a former General Counsel in the pharmaceutical industry and is a registered attorney with the Bar of Paris (France) primarily advising biotech, medtech, diagnostic, pharma and IT companies. He has more than 30 years experience in international business law.

See more

Willy Mathot

Willy is a former General Counsel in the pharmaceutical industry and is a registered attorney with the Bar of Paris (France) primarily advising biotech, medtech, diagnostic, pharma and IT companies. He has more than 30 years experience in international business law. After 5 years in two international law firms specialized in international business law and M&A, Willy joins Ipsen, a pharmaceutical company with more than 30 affiliates worldwide, to accompany its international growth and rapidly, he is appointed General Counsel and Chief Compliance Officer. A few of his achievements includes Ipsen industrial implantation in China back in 1992, several M&A operations (UK, USA), 320 M€ IPO on Euronext in 2005 and prevails in all Ipsen litigations, in particular he obtains damages of 39M€ in the USA and 18M€ in France. He is a founder of IBBS. https://willymathot-avocat.com

Dr Gérard Bastian

Nathalie MAZURE

University of Nice Sophia-Antipolis, France

Nathalie Mazure is a senior scientist and research director at the CNRS at the Institute for Research on Cancer and Aging, Nice (IRCAN) in France. Since 1994, she has contributed to the field of hypoxia by understanding the mechanisms of gene regulation under hypoxic conditions.

See more

Nathalie MAZURE

Nathalie Mazure is a senior scientist and research director at the CNRS at the Institute for Research on Cancer and Aging, Nice (IRCAN) in France. Since 1994, she has contributed to the field of hypoxia by understanding the mechanisms of gene regulation under hypoxic conditions. As hypoxia is more a stimulation for the survival of tumor cells, she focused on the resistance to cell death of hypoxic cancer cells. She found that different mechanisms, such as autophagy or microfusion between mitochondria and endolysosomes, confer such a resistance. Recently, her main interest is on hypoxic mitochondria with the objective to identify new targets involved in both metabolism and survival.

Dr GREGOIRE PREVOST

Prof. Enrique Raviña

Professor of Pharmaceutical/Medicinal Chemistry

Enrique Raviña was born in Teo, province of La Coruña, Spain. He has completed his PhD in 1969 and, in 1975 was appointed Professor of Organic Chemistry. Since 1981 until 2012 has been Professor of Pharmaceutical/Medicinal Chemistry at the University of Santiago de Compostela (Spain) where presently is Professor ad honorem .

See more


Prof. Enrique Raviña

Enrique Raviña was born in Teo, province of La Coruña, Spain. He has completed his PhD in 1969 and, in 1975 was appointed Professor of Organic Chemistry. Since 1981 until 2012 has been Professor of Pharmaceutical/Medicinal Chemistry at the University of Santiago de Compostela (Spain) where presently is Professor ad honorem . Professor Raviña has been Dean of the Faculty of Pharmacy (1989-1995).He is a member of Spanish Royal Academy of Pharmacy and a founding member of the Spanish Society of Therapeutical Chemistry. Also, he has been a membership of the American Chemical Society and of its Division of Medicinal Chemistry. Professor Raviña has published more than 120 papers in reputed journals, has been reviewer of the Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry and others and has been Lecturer in American and European Universities. Professor Enrique Raviña is author of several books dealing with the evolutionary road in Drugs Discovery: 1).Medicamentos. Un viaje a lo largo de la evolución histórica del descubrimiento de fármacos (in Spanish) 2.vols. University of Santiago de Compostela, Spain, 2008. 2).The Evolution of Drug Discovery. From traditional medicines to modern drugs.Wiley-VCH (Weinheim, Germany) 2011[book review ChemMedChem 2011, 6, 1746-1747] 3).Las Medicinas de la Historia Española en América/ Medicines of Spanish History from America. English/Spanish bilingual edition. Co-edition by Fundación Lilly and University of Santiago de Compostela, 2017 [book review J.Ethnopharmacology &Asian Foods, 2019, 4, 3]

Dr Gérard Bastian

Dr Gérard Bastian

Visiting research specialist at the University of New Orleans in Louisiana

Dr Gérard Bastian was head of the Oncopharmacology laboratory which is part of the Pharmacology department at the Pitié-Salpétrière hospital in Paris. He is involved in translational research starting from testing new chemicals for their potential antitumor activity against human tumor cell lines

See more

Dr Gérard Bastian

Dr Gérard Bastian was head of the Oncopharmacology laboratory which is part of the Pharmacology department at the Pitié-Salpétrière hospital in Paris. He is involved in translational research starting from testing new chemicals for their potential antitumor activity against human tumor cell lines, measuring by Flow cytometry the effect of such compounds on the cell cycle, the apoptosis induction and looking at the uptake and efflux inside the cells, nucleus and DNA. He is also involved in clinical trial studying the pharmacokinetics of new drugs during phase I and Phase II trial with a special focus on drug interaction. He is also involved in posology adaptation research based on patient’s characteristics. Actually, he is a visiting research specialist at the University of New Orleans in Louisiana (USA) to work on the phase II trial of a new antitumor agent.

Dr Gérard Bastian

Alain Zozime

PhD

I got my PhD specialty Solid State Physics in 1977 at the University Paris 13, France. I worked in the “Materials Physics Laboratory” of the CNRS in Meudon, France, where I studied stoichiometry and optical properties of Cdx Hg1-x Te semiconductor thin films for IR detection...

See more

Alain Zozime

I got my PhD specialty Solid State Physics in 1977 at the University Paris 13, France. I worked in the “Materials Physics Laboratory” of the CNRS in Meudon, France, where I studied stoichiometry and optical properties of Cdx Hg1-x Te semiconductor thin films for IR detection, laid out by cathodic sputtering. Then in collaboration with the 4th Physics Institute of the University Göttingen, Germany, I studied the electrical properties of extended defects in CdTe and InP, as well as those of Si multicrystalline solar cells in order to increase the conversion yield. After 30 years spent in the field of semiconductor research, I began a new research activity moving to the University of Evry (UEVE), France, at the time where the biocluster Genopole was created. I initiated a research group “Physics and Chemistry of Life” where we studied the DNA-protein/drugs interaction using Atomic Force Microscopy. This group is now part of the “Structure and Properties of Normal and Pathogenic Biomolecules Laboratory” in the campus UEVE-Genopole.

Fabrice Beauchêne

Fabrice Beauchêne

Founder, Owner and CEO of My Pharma Company

Fabrice is a serial entrepreneur, with more than 20 years experience in life science busineses,IT projects management and fund raising.

See more

Fabrice Beauchêne

Fabrice is a serial entrepreneur, with more than 20 years experience in life science busineses,IT projects management and fund raising.

Sylvie Kahn

Sylvie Kahn

Vice-President, Worldwide Operations at Popsi Cube

Sylvie has more than 30 years in Clinical Development of drugs and medical devices in top 10 Pharma and CROs. She is a certified trainer in Clinical Research.

See more

Sylvie Kahn

Sylvie has more than 30 years in Clinical Development of drugs and medical devices in top 10 Pharma and CROs. She is a certified trainer in Clinical Research.

PENG YU, Ph. D.

Professor Didier Desmaele

Medicinal Chemistry, Université Paris Sud, France

Didier Desmaële earned his PhD at the University P&M Curie (Paris, France) in 1984, working on the total synthesis of 1,25-dihydroxycholecalciferol under the supervision of Pro.

See more

Professor Didier Desmaele

Didier Desmaële earned his PhD at the University P&M Curie (Paris, France) in 1984, working on the total synthesis of 1,25-dihydroxycholecalciferol under the supervision of Pro. Jacqueline Ficini. After a post-doctoral research position at Yale University in the group of Professor S. L. Schreiber where he studied the Paterno-Büchi reaction, he was appointed scientist at the CNRS where he developed new asymmetric synthesis methodologies and natural product syntheses. In 1992, he moved to the school of Pharmacy of Paris-Sud University and took the position of head of team within the CNRS research unit BIOCIS and got promoted CNRS Research Director in 2014. His main topics of interest were the total synthesis of natural products including alkaloids and terpenes, asymmetric synthesis and medicinal chemistry. In January 2011, he joined the Institut Galien at the University Paris-Sud. His current research activities focus on the design and the synthesis of lipidic and polymeric bioconjugates for nanoparticular drug delivery. He is (co)author of 180 peer review articles in international journals, 12 patents and 8 book chapters.

PENG YU, Ph. D.

Christian Cavé

Ph.D

Professor Christian Cavé received his Pharm D in 1980 and this Ph. D. in 1986 from Paris Sud University.

See more

Christian Cavé

Professor Christian Cavé received his Pharm D in 1980 and this Ph. D. in 1986 from Paris Sud University. From 1986 to 1990, he was project leader in Medicinal Chemistry (Meram Laboratories, France). Then he worked , as assistant professor (1990-1997) at the Faculty of Pharmacy of University Paris in the Group of Organic Chemistry ( Professor Jean D'Angelo) and as full professor of Organic Chemistry at University of Burgandy (Dijon) . Then he moved to Faculty of Pharmacy of University Paris Sud in 2002 and he is a full Professor from 2002.. He was the Head of the research team "Organic chemistry and pharmacochemistry " in the UMR CNRS BioCIS (2002/2008) and then joined the group of Antiparasite Chemotherapy , UMR-CNRS BioCIS 8076, at the Faculty of de Pharmacy, University Paris-Saclay. His research interests comprise synthetic organic; Asymmetric synthesis: Asymmetric Michael Reaction; Medicinal Chemistry in the field of alzheimer’ disease, HIV, cancer, leishmaniasis, and malaria; Pharmaceutical Chemistry: Biotransformation, QSAR In Organic Chemistry, we develop synthetic tools that we then use in medicinal chemistry.For example, we have developed the Asymmetric Michael reaction onto acyclic ketones or acyclic or acyclic  ketoesters via chiral imines or enaminoesters derivatives Thus, new chiral ketophosphonates and new chiral -hydroxy esters have been made in order to have access to new analogues of metabotropic glutamate receptors that are highly involved in Alzheimers Disease. Currently we are working on click chemistry in order to synthesize new compounds usable in medicinal chemistry. He is the author or co-author of over 90 scientific papers. He is responsible for the Master degree in Pharmaceutical sciences- https://www.universite-paris-saclay.fr/fr/formation/master/sciences-du-medicament#mention He is member of executive committee of school " Biology, Medecine and pharmacy", University Paris Saclay He is Member of editorial boards of various chemical and pharmaceutical reviews; He is member of Executive Committee of European Association of Faculties of Pharmacy (EAFP) https://www.eafponline.eu, member of Executive Committee of Société de Chimie Thérapeutique (French Society of Medicinal Chemistry) https://www.sct-asso.fr/, member of ACS (American Chemical Society) and SFC (French Chemical Society). he has received many honors: Graduate of the Faculty of Pharmacy Paris-Sud; Auguste Béhal Prize for studies and researches, Roussel Prize for Researches in the field of Medicinal Chemistry, Chevalier dans l’ordre des palmes académiques Member of UiTM Academic Advisory Panel for Faculty of Pharmacy, Kuala Lumpur, Malaisie, visiting Professor at Guiyang College of Traditional Chinese Medicine, guest professor of Guizhou Institut of Technology.

Olivier Lavergne

Dr Olivier Lavergne

Founder and CEO of Chem4LS, a consultancy in medicinal chemistry and preclinical research.

Dr Olivier Lavergne is the founder and CEO of Chem4LS, a consultancy in medicinal chemistry and preclinical research

See more

Dr Olivier Lavergne

Dr Olivier Lavergne is the founder and CEO of Chem4LS, a consultancy in medicinal chemistry and preclinical research. After studying industrial chemistry in Lyon 5France) he moved to Wayne State University in Detroit (Michigan) where he obtained his PhD with Pr Carl Johnson. Starting his carreer with the Beaufour-Ipsen group in Barcelona (Spain) and pursuing at the Henri Beaufour Institute in Paris (France), he has contributed to numerous research projects with small molecules, peptides and small proteins. Dr Lavergne has extensive experience in drug design in disease areas spanning oncology, endocrinology and CNS, employing a wide array of approaches including immune check-point modulation, DNA intercalation, cross-linking and damaging agents, cell cycle control check-points, steroid-cascade enzymes inhibition, phosphatase and kinase inhibitors, GPCR ligands and allosteric modulation. Dr Lavergne current research interests include novel modalities of drug discovery including Deap Learning methods. Contact email: ol.chem4ls@gmail.com

PENG YU, Ph. D.

Professor Jianfeng LIU

Ageing and GPCR specialist

Vice director,Key laboratory of molecular biophysics of ministry of education - HUST Wuhan, China

See more

Professor Jianfeng LIU

Vice director,Key laboratory of molecular biophysics of ministry of education - HUST Wuhan, China

Dr. Yongmin Zhang

Dr. Yongmin Zhang

Ph.D. of Medicinal Chemistry at South Paris University

Dr. Yongmin Zhang graduated from the School of Pharmaceutical Sciences of Beijing Medical University in 1982. He got his Ph.D.

See more

Dr. Yongmin Zhang

Dr. Yongmin Zhang graduated from the School of Pharmaceutical Sciences of Beijing Medical University in 1982. He got his Ph.D. of Medicinal Chemistry at South Paris University in 1986. After two years post-doc research at Beijing Medical University, he worked as visiting associate professor then visiting professor at South Paris University prior to taking a permanent position at French CNRS in 1991, where he is now first class research director and Ph.D. supervisor at the CNRS-Sorbonne University joint molecular chemistry institute. He is laureate of several research awards, such as “Prize of medicinal chemistry research” which he got from the 25th International Meeting of Medicinal Chemistry. He worked as visiting scholar at University of Washington in United States during 1995-1997. He was elected member of French National Academy of Pharmacy in 2012. Inventor of 5 patents, Dr. Yongmin Zhang has published more than 200 original research papers. His current research interests include biologically active oligosaccharides, glycosphingolipids, carbohydrate-carbohydrate interaction, carbasugars, azasugars, modified cyclodextrins, and fullerene chemistry, aiming at the carbohydrate-based drug development.

Hervé Galons

Hervé Galons

Université René Descartes

The research is organized in two different labs: The University in Paris and the biotech company: ManRos Therapeutics founded in 2007 with Dr Laurent Meijer.

See more

Hervé Galons

The research is organized in two different labs: The University in Paris and the biotech company: ManRos Therapeutics founded in 2007 with Dr Laurent Meijer. In both labs most of the ongoing research programs are related to kinase inhibition or compounds to treat diseases related to protein misfolding. These two labs have their own complete equipment for chemistry including a 400 MHz NMR apparatus. A collaboration was recently started with the Med Chem lab directed by Prof. Yu Peng at Tianjin University for Science and Technology.

Philippe Rondard

Philippe Rondard

Ph.D

Institut de Génomique Fonctionnelle (IGF),UMR5203 CNRS, U1191 INSERM, Université de Montpellier, France

See more

Philippe Rondard

Philippe Rondard received his Ph.D from the University of Paris 7 in 1998. During the period of 1993-1998, he was trained at Pasteur Institute (Paris, France) in protein biochemistry. In 1998, he joined Henry Bourne's laboratory at University of California San Francisco, as a postdoctoral fellow. He studied the molecular mechanism of G-protein activation. Since 2001, he is working within Jean-Philippe Pin's laboratory. Since 2008, he’s leading a research group within this laboratory. Dr. Rondard's main research interest has been the molecular mechanism of activation of class C G protein-coupled receptors (GPCRs) with focus on the metabotropic glutamate and GABA-B receptors. He has developed several biochemical and biophysical approaches based on the technique of time-resolved FRET. Recently, he developed single domain antibodies from llamas (nanobodies) to detect and modulate GPCR signaling.

Hélène Castel

Chemotactic GPCRs in Glioma Development and Recurrence

See more

Hélène Castel

Hélène Castel started to develop different variants of the electrophysiological technique at the University of Rouen in the Neuroendocrinology laboratory of Dr Vaudry (U413 Inserm) to give a comprehensive view of modulation of the GABAA receptor-channel function by interacting proteins in the central nervous system. She received her PhD in Neurosciences, Molecular and Cell Biology at the Rouen University in 2000. She then spent 2 years on a post-doctoral position in the Pr Colquhoun’s laboratory at University College of London, UK. There, she has developed fast-concentration-jump techniques to mimic electrical fast synaptic inputs on recombinant NMDA receptors and acquired expertise in molecular biology through mutagenesis of NMDA receptor subunits. In 2002, she obtained a permanent position as Chargée de Recherche (CR) at Inserm and became in 2010 leader of the team “Astrocyte and Vascular Niche”. She is now Research Director at Inserm and co-head of the international platform “Cancer and Cognition” under the French North-West Canceropole. She published 90 scientific papers and gave 40 national or international conferences. She develops translational projects on G-protein-coupled receptors (GPCRs) and G proteins in cerebro-glio-vascular pathologies including the development of high-grade gliomas (angiogenesis and invasion), on molecular signalings and cellular mechanisms of chemotactic cell migration, on the impact of cancer and cancer therapies on brain function, on new strategies for prevention of cognitive dysfunctions induced by chemotherapy and on local strategies for glioblastoma treatment and functional rehabilitation in preclinical models.

PENG YU, Ph. D.

Dr. ERIC CHEVET

Ph.D

Eric Chevet is Research Director at the French National Institute for Health and Medical Research (Inserm).

See more

PENG YU

Education （in time-reversed order） 2003 Habilitation to supervise research (HDR); University of Evry 1996 PhD, University of PARIS XI Research Experience （in time-reversed order） Since Jan 2017 – DR1 INSERM, dir. INSERM U1242, Univ. Rennes 1, CLCC Eugène Marquis, Rennes. March 2015 – Dec 2016 – DR2 INSERM, ER440 Univ. Rennes 1, CLCC Eugène Marquis, Rennes. Jan 2010- present – DR2 INSERM U1053, Bordeaux Jan 2007- Jan 2012 – Head Team Avenir, “Endoplasmic Reticulum stress & cancer” Dec 2006- Dec 2010 - Researcher (CR1) INSERM U1053, Bordeaux Sept 2001-Dec 2006 – Assistant Professor, McGill University, Montreal, Qc, Canada Jan 1997- Aug 2001 - Post-Doctoral fellow, McGill University, Montreal, Qc, Canada Sept 1993 – Dec 1996 – PhD Thesis, Univ. PARIS XI, France Summary academic achievements: Eric Chevet is Research Director at the French National Institute for Health and Medical Research (Inserm). After a Ph.D. in Molecular Cell Biology from the University of Paris in 1996 and a post-doctoral fellowship at McGill University (Canada), he established his own laboratory at McGill University in 2001 before going back to France in 2006. For the past 15 years he has been investigating the role of endoplasmic reticulum stress signaling and proteostasis control in cancer development. Early 2015, he moved to Rennes in the West part of France to head a Cancer Research Laboratory within the Comprehensive Cancer Centre Eugène Marquis”. The main objective of this research centre will be to characterize select stress signaling pathways (including ER stress, death receptors, DNA damage) in various cancers and develop novel relevant therapeutics to impede cancer development. Eric Chevet has authored more than 140 publications and few patents.

Dr. Bertrand Duvillié

Ph.D

See more

Dr. Bertrand Duvillié

Following his graduation in genetics at University Paris 7 (M Sc.), Bertrand Duvillié studied brain development for one year in the laboratory of Dr Charnay at Ecole Normale Supérieure (Paris, France). Next, he oriented his educational cursus on pancreas development. Indeed, his objective was to understand the mechanisms that control the pancreatic progenitor cell differentiation into mature beta cells and to contribute on a long term to define new protocols for a cell-therapy of diabetes. Thus, he joined the team of Dr Jami for his PhD (Cochin Institute, Paris) where he generated and analyzed insulin 1 and insulin 2 mutant mice in order to decipher the roles of embryonic insulin in pancreas development. To deepen his knowledge in the effect of growth factors, he next spent 3 years at London (Ontario, Canada), in the laboratory of Prof. David J. Hill. In particular, he analyzed the effects of Insulin-like Growth Factors on the proliferation and survival of pancreatic islet cells. In 2000, he was recruited at INSERM as a researcher in the laboratory of Prof. Czernichow. From 2000 to 2006, he worked with Dr R Scharfmann, and he studied the role of Fibroblast Growth Factors in pancreas development, both in rodents and humans. He also investigated the effects of the mesenchyme on beta-cell development through the activation of the Notch pathway. Since 2006 to 2016, he continued his research as a junior group leader, in the same unit (directed by Dr Scharfmann at Faculty Necker 2006-2011, and next at Cochin Institute 2012-2016). His investigations were focused on the role of environmental factors in pancreas development. In particular, he showed that not only oxygen tension, but also reactive oxygen species (ROS) control the expression of the pro-endocrine transcription factor Ngn3 in the pancreas. Since 2016, Bertrand Duvillié joined the laboratory of Celio Pouponnot and Alain Eychene at the Curie Institute. His global objective is to better understand the signals that control endocrine tumorigenesis. In particular he aims to analyze the role of intra-cellular signals using engineered mice models that mimic human pathologies.

Submit an abstract to Xi’an Convention 2019.

The attendees have the opportunity to present their own activities during the 2 days sessions. Individuals interested in submitting an abstract must do so by email to contact@ibbs-services.com by August 31, 2019 deadline. The combined length of the abstract title, list of authors, email address of the presenter and body text should not exceed 4,000 characters. Abstracts should be carefully reviewed prior to submission for content errors, spelling, names, etc. Notifications of abstract receipt will be sent to the abstract submitter indicating the modalities of presentation on September 10, 2019.

Note: Submitting an abstract for presentation does not constitute registration for the meeting.

Draft program

PROGRAM - Cancer and Biomarkers, from Bench to Market

Meeting room: Xidian University,School of Life Science and Technology, G-420 room



Newsletter Sign Up

No Spam - Only latest news, price and activity updates

Registration

Registration fee in EURO



Students Pass
€100
  • Only for students
  • Plenary Sessions Access
  • Business Convention Access
  • Educational Sessions Access
  • Free snacks
Academics Pass
€200
  • Only for academics
  • Plenary Sessions Access
  • Business Convention Access
  • Educational Sessions Access
  • Free snacks
Normal Pass
€400
  • For all
  • Plenary Sessions Access
  • Business Convention Access
  • Educational Sessions Access
  • Free snacks

To register on line

Complete the following form to register

6 + 3 = ?
Participant's testimony

what people say previous editions

I’m a medical student who studied in Wuhan, China, and then in Toulouse, France for my PhD. I had the pleasure to be invited to the sino-french conference which took place in China, in the city where I have done my study. I found the conference was well organized.

See more

Doctor Lingli Yuan

I’m a medical student who studied in Wuhan, China, and then in Toulouse, France for my PhD. I had the pleasure to be invited to the sino-french conference which took place in China, in the city where I have done my study. I found the conference was well organized. It was a good opportunity to learn new things, to see on which topics the others are working. Among others, I have learned facts about evolution of radiotherapy and its limitation, about the limitation of chemotherapy and its potential solution. I also had the opportunity to see what drug we are trying to develop currently. It was also a good occasion to meet other researchers and be to get to know new person. It was also for the student a good place to find PHD, a post-doc or another job. On the opposite, it was a good occasion for the teacher to find student for their open positions. According to me, more international conference shall be organized in China. All students do not have the chance to go abroad for conference and it is also a chance for experts to discover China (of course the country! but also the team of researchers and their labs). Besides science, the conference was also a good way to exchange about cultures: For foreigners to experience the Chinese way of life and for the Chinese to take part to a wine tasting. In a nutshell, I found that this kind of conference is really helpful to build a platform for good international communication and to find potential need of each other.

Doctor Lingli Yuan Doctor
The “Joint Course of the Sino-French School of Oncology” was a really nice scientific meeting. I had the chance to give a short lecture and I appreciated the discussions I had with others speakers after my talk. Apart from the scientific knowledge I gained through very interesting conferences,

See more

Marine Garrido

The “Joint Course of the Sino-French School of Oncology” was a really nice scientific meeting. I had the chance to give a short lecture and I appreciated the discussions I had with others speakers after my talk. Apart from the scientific knowledge I gained through very interesting conferences, this congress was also the perfect occasion to know more about the research facilities in China. I was really impressed by the very modern equipments they have in Biolake. For sure, those visits will raise interests of French researchers for new collaborations with Chinese labs. The relationships between the researchers were really pleasant, allowing a great atmosphere during the congress but also during the different activities organized in Wuhan and nearby. Moreover, the Chinese students in charge of the organization were really kind, always available and helpful. We could feel that they were happy to do some sightseeing with us. We shared some good times with them (nice dinners for instance) so we could exchange about cultural differences. No negative points, unbelievable but true! Thank you Wuhan, I would be glad to see you again!!

Marine Garrido Ph Student
As a PhD student in Paris, I was very glad to have the opportunity to attend Sino-French School of Oncology in Wuhan. It was an inspiring and successful conference. The conference was indeed an excellent occasion for researchers around the world to come together and share their research.

See more

Zhenyu WANG

As a PhD student in Paris, I was very glad to have the opportunity to attend Sino-French School of Oncology in Wuhan. It was an inspiring and successful conference. The conference was indeed an excellent occasion for researchers around the world to come together and share their research. It did not only give the researchers in China an opportunity to learn directly from overseas researchers, it also helped make the research in China known to researchers from other countries. It was definitely a great way to promote the research in China, France and other countries. This conference was a very valuable experience for me. The invited speakers delivered insightful presentations on current research issues. I learned a great deal from numerous innovative studies presented at the conference. Moreover, I had an opportunity to give a short lecture and through presenting my own work I was able to obtain invaluable feedback from various researchers in the area. Overall, it was a very satisfying experience.

Zhenyu WANG PhS Student

Present your Innovative projects under spotlights

Submit an abstract for your oral presentation or poster session

5 + 3 = ?
Sponsors

Special thanks to our distinguished sponsors



Sponsor Services

IBBS offers to optimize your trip to China by organizing a personalized program of appointments with potential Chinese partners.

This program will be customized to your needs, organized on the basis of an estimate, and will aim to make you meet with potential partners (academics, pharma and medtech, investors, distributors, etc.). For more information, thank you to contact IBBS (contact@ibbs-services.com).



IBBS

Official carrier

The official carrier of the event is Air France-KLM:
Travel with our official carrier and get discount on your airplane ticket using the conference code 35266AF :


Book Your Airplane Ticket
Housing

Official Hotel： Hilton Garden Inn Xi'an Hi-Tech Zone / Download Hotel Infonrmations

Address and Contacts




Location
  • Xidian University,School of Life Science and Technology, G-420 room
  • contact@ibbs-services.com
  • ...
  • 7:30 - 22:00
Mail Us

5 + 3 = ?

IBBS-SERVICES

All Rights Reserved © 2019

Event Registration

Soon available